样式: 排序: IF: - GO 导出 标记为已读
-
A neoteric annotation on the advances in combination therapy for Parkinson’s disease: nanocarrier-based combination approach and future anticipation. Part II: nanocarrier design and development in focus Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-03-20 Devika Unnithan, Ali Sartaj, Mohammad Kashif Iqubal, Javed Ali, Sanjula Baboota
The current treatment modalities available for Parkinson’s disease (PD) prove inadequate due to the inherent constraints in effectively transporting bioactive compounds across the blood-brain barri...
-
Ferulic Acid’s therapeutic odyssey: nano formulations, pre-clinical investigations, and patent perspective Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-03-15 Sanshita, Monika, Snigdha Chakraborty, Oluwatoyin Adepeju Odeku, Inderbir Singh
Published in Expert Opinion on Drug Delivery (Just accepted, 2024)
-
A neoteric annotation on the advances in combination therapy for Parkinson’s disease: nanocarrier-based combination approach and future anticipation. Part I: exploring theoretical insights and pharmacological advances Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-03-14 Devika Unnithan, Ali Sartaj, Mohammad Kashif Iqubal, Javed Ali, Sanjula Baboota
Parkinson’s disease is a neurological condition defined by a substantial reduction in dopamine-containing cells in the substantia nigra. Levodopa (L-Dopa) is considered the gold standard in treatme...
-
Recent advances in the application of clay-containing hydrogels for hemostasis and wound healing Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-03-11 Xiaojuan Huang, Bin Hu, Xinyuan Zhang, Peng Fan, Zheng Chen, Shige Wang
Immediate control of bleeding and anti-infection play important roles in wound management. Multiple organ dysfunction syndrome and death may occur if persistent bleeding, hemodynamic instability, a...
-
Do the chitosan nanoparticles really augment the drugs’ transdermal fluxes: ending the debate using meta-analysis Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-03-01 Rania M. Hathout, Rania A.H. Ishak, Doaa H. Shakshak
Transdermal delivery has been extensively investigated as a successful alternative to the oral and parenteral routes of administration. The use of polymeric nanoparticles as drug delivery systems t...
-
Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-28 Javed Ahmad, Javed Ahamad, Mohammed S. Algahtani, Anuj Garg, Naiyer Shahzad, Mohammad Zaki Ahmad, Syed Sarim Imam
Triple-negative breast cancer (TNBC) presents unique challenges in diagnosis and treatment. Resveratrol exhibits potential as a therapeutic intervention against TNBC by regulating various pathways ...
-
MDSC-targeted liposomal all-trans retinoic acid suppresses mMdscs and improves immunotherapy in HBV infection Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-26 Samuel Kesse, Yuhong Xu, Sanyuan Shi, Shanshan Jin, Shafi Ullah, Yongchao Dai, Miao He, Anjie Zheng, Fengwei Xu, Zixiu Du, Raphael N. Alolga, Jinliang Peng
Myeloid-derived suppressor cells (MDSCs) are evolving as a prominent determinant in cancer occurrence and development and are functionally found to suppress T cells in cancer. Not much research is ...
-
Programmable intratumoral drug delivery to breast cancer using wireless bioelectronic device with electrochemical actuation Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-23 Mohammad Souri, Sohail Elahi, Madjid Soltani
Breast cancer is a global health concern that demands attention. In our contribution to addressing this disease, our study focuses on investigating a wireless micro-device for intratumoral drug del...
-
Nanomicellar eye drops: a review of recent advances Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-23 Valentina Paganini, Patrizia Chetoni, Mariacristina Di Gangi, Daniela Monti, Silvia Tampucci, Susi Burgalassi
Research on nanotechnology in medicine has also involved the ocular field and nanomicelles are among the applications developed. This approach is used to increase both the water solubility of hydro...
-
Nanocarriers in topical photodynamic therapy Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-20 Nina Dragicevic, Jelena Predic-Atkinson, Bojan Nikolic, Snezana B. Pajovic, Sanja Ivkovic, Miroslav Adzic
Photodynamic therapy (PDT) has gained significant attention due to its superiority over conventional treatments. In the context of skin cancers and nonmalignant skin diseases, topical application o...
-
An update on strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery: exploiting transformability and bioactivity of PLN and harnessing intracellular lipid transport mechanism Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-18 Taksim Ahmed, Fuh-Ching Franky Liu, Xiao Yu Wu
Polymer-lipid hybrid nanoparticle (PLN) is an emerging nanoplatform with distinct properties and functionalities from other nanocarrier systems. PLN can be optimized to overcome various levels of d...
-
Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-02-02 Evelyn Cottell, Damien Michalet, Monica Lispi, Thiago Dantas Araujo, Ralf Gleixner, Salvatore Longobardi, Thomas D’Hooghe
This study aimed to confirm that the incremental dose/clicks system dispenses accurate doses for the Merck family of fertility pen injectors.Set doses (Vset) for three dose dial settings (minimum d...
-
Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Mohamed El-Tanani, Hamdi Nsairat, Alaa A. Aljabali, Ismail I. Matalka, Alaaldin M. Alkilany, Murtaza M. Tambuwala
The resistance to chemotherapy is a significant hurdle in breast cancer treatment, prompting the exploration of innovative strategies. This review discusses the potential of dual-loaded liposomal c...
-
Engineered exosomes derived from stem cells: a new brain-targeted strategy Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Waqas Ahmed, Songze Huang, Lukui Chen
Using engineered exosomes produced from stem cells is an experimental therapeutic approach for treating brain diseases. According to reports, preclinical research has demonstrated notable neurogene...
-
Lipidated brush-PEG polymers as low molecular weight pulmonary drug delivery platforms Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Lisa M Kaminskas, Neville J Butcher, Christopher N Subasic, Ashok Kothapalli, Shadabul Haque, James L Grace, Alexander Morsdorf, Joanne T Blanchfield, Andrew K. Whittaker, John F Quinn, Michael R Whittaker
Nanomedicines are being actively developed as inhalable drug delivery systems. However, there is a distinct utility in developing smaller polymeric systems that can bind albumin in the lungs. We th...
-
Conjugates of amphotericin B to resolve challenges associated with its delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Vineet Kumar Jain, Keerti Jain, Harvinder Popli
Amphotericin B (AmB), a promising antifungal and antileishmanial drug, acts on the membrane of microorganisms. The clinical use of AmB is limited due to issues associated with its delivery includin...
-
Progress and challenges in intravesical drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Arpita Banerjee, Dongtak Lee, Christopher Jiang, Rong Wang, Zoe Bogusia Kutulakos, Sohyung Lee, Jingjing Gao, Nitin Joshi
Intravesical drug delivery (IDD) has gained recognition as a viable approach for treating bladder-related diseases over the years. However, it comes with its set of challenges, including voiding di...
-
A review on the use of extracellular vesicles for the delivery of drugs and biological therapeutics Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Sundus Jabeen Amina, Tasmia Azam, Fatima Dagher, Bin Guo
Exosomes, a type of extracellular vesicles, are effective tools for delivering small-molecule drugs and biological therapeutics into cells and tissues. Surface modifications with targeting ligands ...
-
Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Huixian Tian, Minsi Chang, Yanlin Lyu, Nan Dong, Nini Yu, Tian Yin, Yu Zhang, Haibing He, Jingxin Gou, Xing Tang
Exendin-4 (Ex4) is a promising drug for diabetes mellitus with a half-life of 2.4 h in human bodies. Besides, the Ex4 formulations currently employed in the clinic or under development have problem...
-
Blood–brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Patrick T. Ronaldson, Thomas P. Davis
Successful neuropharmacology requires optimization of CNS drug delivery and, by extension, free drug concentrations at brain molecular targets. Detailed assessment of blood–brain barrier (BBB) phys...
-
The quest to deliver high-dose rifampicin: can the inhaled approach help? Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Prakash Khadka, Jack Dummer, Philip C. Hill, Shyamal C. Das
Tuberculosis (TB) is a global health problem that poses a challenge to global treatment programs. Rifampicin is a potent and highly effective drug for TB treatment; however, higher oral doses than ...
-
Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Noa Fine-Shamir, Arik Dahan
Tackling low water solubility of drug candidates is a major challenge in today’s pharmaceutics/biopharmaceutics, especially by means of modern solubility-enabling formulations. However, drug absorp...
-
Polypeptides as alternatives to PEGylation of therapeutic agents Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Huali Chen, Qianyu Zhang
Due to the concerns raised by the extensive application of PEGylation, polypeptides have stood out as excellent candidates with adequate biocompatibility and biodegradability with tunable hydrophil...
-
Development of a multi-component gastroretentive expandable drug delivery system (GREDDS) for personalized administration of metformin Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-31 Marco Uboldi, Arianna Chiappa, Margherita Rossi, Francesco Briatico-Vangosa, Alice Melocchi, Lucia Zema
Efficacy and compliance of type II diabetes treatment would greatly benefit from dosage forms providing controlled release of metformin in the upper gastrointestinal tract. In this respect, the fea...
-
Recent advances in nanocrystal-based technologies applied for ocular drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-30 Feiyang Geng, Xingyan Fan, Yu Liu, Weiyue Lu, Gang Wei
The intricate physiological barriers of the eye and the limited volume of eye drops impede efficient delivery of poorly water-soluble drugs. In the last decade, nanocrystals have emerged as versati...
-
3D printing in vaginal drug delivery: a revolution in pharmaceutical manufacturing Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2024-01-18 Sagar Narala, Ahmed Adel Ali Youssef, Siva Ram Munnangi, Nagarjuna Narala, Preethi Lakkala, Sateesh Kumar Vemula, Michael Repka
The Food and Drug Administration’s approval of the first three-dimensional (3D) printed tablet, Spritam®, led to a burgeoning interest in using 3D printing to fabricate numerous drug delivery syste...
-
Recent advancements on in vitro blood-brain barrier model: A reliable and efficient screening approach for preclinical and clinical investigation Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 Snigdha Singh, Mukta Agrawal, Rajat Vashist, Rohit K Patel, Sanchita Dhanchandra Sangave, Amit Alexander
The efficiency of brain therapeutics is greatly hindered by the blood-brain barrier (BBB). BBB’s protective function, selective permeability, and dynamic functionality maintain the harmony between ...
-
Targeted transport of biotherapeutics at the blood-brain barrier Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 Torben Moos, Maj Schneider Thomsen, Annette Burkhart, Eva Hede, Bartosz Laczek
The treatment of neurological diseases is significantly hampered by the lack of available therapeutics. A major restraint for the development of drugs is denoted by the presence of the blood-brain ...
-
Untethered shape-changing devices in the gastrointestinal tract Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 Wangqu Liu, Soo Jin Choi, Derosh George, Ling Li, Zijian Zhong, Ruili Zhang, Si Young Choi, Florin M. Selaru, David H. Gracias
Advances in microfabrication, automation, and computer engineering seek to revolutionize small-scale devices and machines. Emerging trends in medicine point to smart devices that emulate the motili...
-
Strategies to identify, engineer, and validate antibodies targeting blood–brain barrier receptor-mediated transcytosis systems for CNS drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 Eun Seo Choi, Eric V Shusta
Numerous therapeutics for neurological diseases have been developed, but many have failed in clinical trials in part due to limited brain bioavailability, mainly stemming from inefficient transport...
-
Design of experiment (DoE) as a quality by design (QbD) tool to optimise formulations of lipid nanoparticles for nose-to-brain drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 A.C. Correia, J.N. Moreira, J.M. Sousa Lobo, A.C. Silva
The nose-to-brain route has been widely investigated to improve drug targeting to the central nervous system (CNS), where lipid nanoparticles (solid lipid nanoparticles – SLN and nanostructured lip...
-
Delivery of mitochondria-containing extracellular vesicles to the BBB for ischemic stroke therapy Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 Kandarp M. Dave, Donna B. Stolz, Devika S Manickam
Ischemic stroke-induced mitochondrial dysfunction in brain endothelial cells (BECs) leads to breakdown of the blood–brain barrier (BBB) causing long-term neurological dysfunction. Restoration of mi...
-
Silica nanoparticles for brain cancer Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-29 Yuran Feng, Yuxue Cao, Ravi Singh, Taskeen Iqbal Janjua, Amirali Popat
Brain cancer is a debilitating disease with a poor survival rate. There are significant challenges for effective treatment due to the presence of the blood–brain barrier (BBB) and blood–tumor barri...
-
Innovative insight into the mechanism of enantioselective skin permeation for chiral drugs Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Yang Zhang, Xiaowen Liu, Guojing Yu, Hongzhe Gui, Jingteng Chi, Shuhan Liu, Liang Fang, Mingzhe Liu
A profound comprehension of the molecular mechanisms underpinning the enantioselective transdermal permeation of chiral drugs is critical in the design and assessment of transdermal preparations. T...
-
Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Zhouyun Chen, Xiaoxiao Wang, Na Zhao, Haifeng Chen, Gang Guo
Tumors pose a significant global economic and health burden, with conventional cancer treatments lacking tumor specificity, leading to limited efficiency and undesirable side effects. Targeted tumo...
-
RNA aptamer-mediated gene therapy of prostate cancer: lessons from the past and future directions Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Marco Arese, Mohammad Mahmoudian, Federico Bussolino
Prostate cancer (PCa) is one of the most prevalent cancers in the world, and the fifth cause of death from cancer in men. Among the non-surgical treatments for PCa, gene therapy strategies are in t...
-
Oral nanoparticulate drug delivery systems for the treatment of intestinal bowel disease and colorectal cancer Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Flavia Laffleur, Alexander Heinz Mayer
The most popular method for delivering drugs locally and systemically is oral. However, the gastrointestinal tract’s severe physiological (mucosal and enzymatic barrier) and physicochemical (pH) en...
-
Liposome-based vaccines for minimally or noninvasive administration: an update on current advancements Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Matteo Aroffu, Maria Letizia Manca, José Luis Pedraz, Maria Manconi
Vaccination requires innovation to provide effective protection. Traditional vaccines have several drawbacks, which can be overcome with advanced technologies and different administration routes. O...
-
Dimeric ferulic acid conjugate as a prodrug for brain targeting after nasal administration of loaded solid lipid microparticles Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Giada Botti, Anna Bianchi, Alessandro Dalpiaz, Paola Tedeschi, Valentina Albanese, Milena Sorrenti, Laura Catenacci, Maria Cristina Bonferoni, Sarah Beggiato, Barbara Pavan
Ferulic acid (Fer) displays antioxidant/anti-inflammatory properties useful against neurodegenerative diseases. To increase Fer uptake and its central nervous system residence time, a dimeric prodr...
-
Recent advances in dosage form design for the elderly: a review Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Sagar Salave, Pranav Patel, Nimeet Desai, Dhwani Rana, Derajram Benival, Dignesh Khunt, Kasitpong Thanawuth, Bhupendra G Prajapati, Pornsak Sriamornsak
With the increase in the elderly population and the prevalence of multiple medical conditions, medication adherence, and efficacy have become crucial for the effective management of their health. T...
-
Advanced approaches to overcome biological barriers in respiratory and systemic routes of administration for enhanced nucleic acid delivery to the lung Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Gijung Kwak, Daiheon Lee, Jung Soo Suk
Numerous delivery strategies, primarily novel nucleic acid delivery carriers, have been developed and explored to enable therapeutically relevant lung gene therapy. However, its clinical translatio...
-
Novel bio-inspired microneedles for wound healing applications Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Sanshita, Suman Pahal, Vivek Ghate, Inderbir Singh
Published in Expert Opinion on Drug Delivery (Vol. 20, No. 11, 2023)
-
Recent progress and application of the tetrahedral framework nucleic acid materials on drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Jiajie Li, Ran Yan, Sirong Shi, Yunfeng Lin
The application of DNA framework nucleic acid materials in the biomedical field has witnessed continual expansion. Among them, tetrahedral framework nucleic acids (tFNAs) have gained significant tr...
-
Small patients, big challenges: navigating pediatric drug manipulations to prevent medication errors - a comprehensive review Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Konstantina Chachlioutaki, Christos Gioumouxouzis, Christina Karavasili, Dimitrios G. Fatouros
Medication errors during drug manipulations in pediatric care pose significant challenges to patient safety and optimal medication management. Epidemiological studies have revealed a high prevalenc...
-
Intravenous nanocrystals: fabrication, solidification, in vivo fate, and applications for cancer therapy Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-20 Qing Xia, Jiaqi Shen, Huining Ding, Siyi Liu, Fei Li, Fengqian Li, Nianping Feng
Intravenous nanocrystals (INCs) have shown intrinsic advantages in antitumor applications, particularly their properties of high drug loading, low toxicity, and controllable size. Therefore, it has...
-
3D-printed solid oral dosage forms for mental and neurological disorders: recent advances and future perspectives Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-12-11 Monika Wojtyłko, Dimitrios A. Lamprou, Anna Froelich, Wiesław Kuczko, Radosław Wichniarek, Tomasz Osmałek
3D printing (3DP) applications in medicine are intensively investigated, creating an opportunity to provide patient-tailored therapy by delivering a drug with an accurate dose and release profile. ...
-
Biocompatible smart micro/nanorobots for active gastrointestinal tract drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-30 Baozhen Zhang, Lizhen Zhu, Hong Pan, Lintao Cai
Oral delivery is the most commonly used route of drug administration owing to good patient compliance. However, the gastrointestinal (GI) tract contains multiple physiological barriers that limit t...
-
Designing self-triggered micro/milli devices for gastrointestinal tract drug delivery Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-30 Lijun Cai, Yu Wang, Zhiqiang Luo, Jinglin Wang, Haozhen Ren, Yuanjin Zhao
Self-triggered micro-/milli-devices (STMDs), which are artificial devices capable of responding to the surrounding environment and transferring external energy into kinetic energy, thus realizing a...
-
The crossroad of nanovesicles and oral delivery of insulin Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-30 Mohammad Reza Fadaei, Marzieh Mohammadi, Mohammad Saleh Fadaei, Mahmoud Reza Jaafari
Diabetes mellitus is one of the challenging health problems worldwide. Multiple daily subcutaneous injection of insulin causes poor compliance in patients. Development of efficient oral formulation...
-
A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-17 Steven F. Dowdy, Conor J. Gallagher, Domenico Vitarella, Jessica Brown
Cell-penetrating peptides (CPPs), are small peptides that facilitate cytosolic access and, thus, transport of therapeutic macromolecules to intracellular sites when conjugated to cargo proteins. As...
-
Multifunctional systems based on nano-in-microparticles as strategies for drug delivery: advances, challenges, and future perspectives Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-17 Suzana Gonçalves Carvalho, Aline Martins dos Santos, Amanda Letícia Polli Silvestre, Alberto Gomes Tavares, Marlus Chorilli, Maria Palmira Daflon Gremião
Innovative delivery systems are a promising and attractive approach for drug targeting in pharmaceutical technology. Among the various drug delivery systems studied, the association of strategies b...
-
Microneedles for oral mucosal delivery – Current trends and perspective on future directions Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-17 Luiz E. N. Ferreira, Michelle Franz-Montan, Bruna Benso, Harvinder S. Gill
Oral cavity drug and vaccine delivery has the potential for local targeting, dose reduction, minimization of systemic side effects, and generation of mucosal immunity. To overcome current limitatio...
-
Current status of porous coordination networks (PCNs) derived porphyrin spacers for cancer therapy Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-17 Jeifeng Huang, Donghui Liao, Yuting Han, Ying Chen, Saleem Raza, Chengyu Lu, Jianqiang Liu, Qian Lan
Porous coordination networks (PCNs) have been widely used in large number of applications such as light harvesting, catalysis, and biomedical applications. Inserting porphyrins into PCNs scaffolds ...
-
Nasal delivery as a strategy for the prevention and treatment of COVID-19. Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-10-16 Fabio Sonvico,Gaia Colombo,Eride Quarta,Fabiola Guareschi,Sabrina Banella,Francesca Buttini,Regina Scherließ
INTRODUCTION The upper respiratory tract is a major route of infection for COVID-19 and other respiratory diseases. Thus, it appears logical to exploit the nose as administration site to prevent, fight, or minimize infectious spread and treat the disease. Numerous nasal products addressing these aspects have been considered and developed for COVID-19. AREAS COVERED This review gives a comprehensive
-
Metered dose inhalers in the transition to low GWP propellants: what we know and what is missing to make it happen Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-09-28 Francesca Buttini, Stefania Glieca, Fabio Sonvico, David A. Lewis
The urgency to replace the propellants currently in use with the new sustainable ones has given rise to the need for investigation and reformulation of pMDIs.The reformulation requires in-depth kno...
-
Inhalation delivery of nucleic acid gene therapies in preclinical drug development Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-09-21 Conor A. Ruzycki, Derek Montoya, Hammad Irshad, Jason Cox, Yue Zhou, Jacob D. McDonald, Philip J. Kuehl
Inhaled gene therapy programs targeting diseases of the lung have seen increasing interest in recent years, though as of yet no product has successfully entered the market. Preclinical research to ...
-
Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-09-16 Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, Mario Cazzola, Paola Rogliani
ABSTRACT Introduction Monoclonal antibodies (mAbs) should be administered by inhalation rather than parenterally to improve their efficiency in lung diseases. However, the pulmonary administration of mAbs in terms of aerosol technology and the formulation for inhalation is difficult. Areas covered The feasible or suitable strategies for overcoming the barriers associated with administering mAbs are
-
Receptor–mediated transcytosis of macromolecules across the blood–brain barrier Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-09-15 Habib Baghirov
The blood–brain barrier (BBB) restricts brain access of virtually all macromolecules. Receptor-mediated transcytosis (RMT) is one strategy toward their brain delivery. In this strategy, targeting l...
-
Alternative application of an iTrack microcatheter and canaloplasty: case report and literature review Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-09-12 Aleksandra K. Kicińska, Marek Rękas
Glaucoma is the leading cause of irreversible blindness worldwide. Schlemm’s canal surgery using an iTrack flexible microcatheter has become popular because of its high quality-of-life issues and t...
-
Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson’s disease: is it an improvement on other delivery? Expert Opin. Drug Deliv. (IF 6.6) Pub Date : 2023-09-10 Sheila A Doggrell
Parkinson’s disease (PD) is the second most common neurodegenerative disease and is growing in prevalence and disability. The standard treatment for PD is oral levo-dopa (LD) with carbidopa (CD). A...